NASDAQ:LJPC - La Jolla Pharmaceutical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.51 -0.01 (-0.13 %) (As of 04/24/2019 09:48 AM ET)Previous Close$7.52Today's Range$7.4501 - $8.0052-Week Range$5.01 - $38.39Volume305,448 shsAverage Volume904,684 shsMarket Capitalization$203.34 millionP/E RatioN/ADividend YieldN/ABeta1.32 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product to treat conditions characterized by iron overload, including hereditary hemochromatosis, beta thalassemia, sickle cell disease, myelodysplastic syndrome, and polycythemia vera. The company was founded in 1989 and is headquartered in San Diego, California. Receive LJPC News and Ratings via Email Sign-up to receive the latest news and ratings for LJPC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LJPC Previous Symbol CUSIPN/A CIK920465 Webwww.lajollapharmaceutical.com Phone858-207-4264Debt Debt-to-Equity RatioN/A Current Ratio5.95 Quick Ratio5.88Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10.06 million Price / Sales20.21 Cash FlowN/A Price / Cash FlowN/A Book Value$1.12 per share Price / Book6.71Profitability EPS (Most Recent Fiscal Year)($7.85) Net Income$-199,470,000.00 Net Margins-1,983.58% Return on Equity-223.23% Return on Assets-88.51%Miscellaneous Employees169 Outstanding Shares27,076,000Market Cap$203.34 million Next Earnings Date5/9/2019 (Estimated) OptionableOptionable La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions What is La Jolla Pharmaceutical's stock symbol? La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC." How were La Jolla Pharmaceutical's earnings last quarter? La Jolla Pharmaceutical (NASDAQ:LJPC) issued its quarterly earnings data on Monday, March, 4th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.74) by $0.01. The biopharmaceutical company earned $4.18 million during the quarter, compared to the consensus estimate of $4.20 million. La Jolla Pharmaceutical had a negative return on equity of 223.23% and a negative net margin of 1,983.58%. View La Jolla Pharmaceutical's Earnings History. When is La Jolla Pharmaceutical's next earnings date? La Jolla Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for La Jolla Pharmaceutical. What guidance has La Jolla Pharmaceutical issued on next quarter's earnings? La Jolla Pharmaceutical updated its FY 2019 earnings guidance on Monday, March, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $24-28 million, compared to the consensus revenue estimate of $40.28 million. What price target have analysts set for LJPC? 6 Wall Street analysts have issued 12 month price objectives for La Jolla Pharmaceutical's shares. Their forecasts range from $6.00 to $115.00. On average, they expect La Jolla Pharmaceutical's share price to reach $35.00 in the next year. This suggests a possible upside of 359.9% from the stock's current price. View Analyst Price Targets for La Jolla Pharmaceutical. What is the consensus analysts' recommendation for La Jolla Pharmaceutical? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for La Jolla Pharmaceutical. What are Wall Street analysts saying about La Jolla Pharmaceutical stock? Here are some recent quotes from research analysts about La Jolla Pharmaceutical stock: 1. According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (1/17/2019) 2. HC Wainwright analysts commented, "We are reducing our price target to $25, from $48, due to lower Giapreza sales expectations partially offset by cost cutting expectations in R&D and SG&A. We base our $25 price target on a sum-of-the-parts analysis based on: (1) the P/E value of La Jolla’s current commercial business (Giapreza); (2) an NPV of its pipeline (LJPC-401); and (3) our estimated year- end fully diluted net cash of $4.03/share, which includes the capital raise earlier this year and the royalty agreement, to arrive at our price target. We value the current commercial business at $9.82 per share and the pipeline at $10.83 per share." (1/9/2019) Has La Jolla Pharmaceutical been receiving favorable news coverage? Headlines about LJPC stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. La Jolla Pharmaceutical earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the company's share price in the near future. Who are some of La Jolla Pharmaceutical's key competitors? Some companies that are related to La Jolla Pharmaceutical include NanoString Technologies (NSTG), Nightstar Therapeutics (NITE), BAVARIAN NORDIC/S (BVNRY), Osiris Therapeutics (OSIR), Voyager Therapeutics (VYGR), MeiraGTx (MGTX), Heska (HSKA), DBV TECHNOLOGIE/S (DBVT), Acorda Therapeutics (ACOR), Mesoblast (MESO), Krystal Biotech (KRYS), Avrobio (AVRO), Adaptimmune Therapeutics (ADAP), Replimune Group (REPL) and Scholar Rock (SRRK). What other stocks do shareholders of La Jolla Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other La Jolla Pharmaceutical investors own include El Pollo LoCo (LOCO), Intercept Pharmaceuticals (ICPT), BioCryst Pharmaceuticals (BCRX), Juno Therapeutics (JUNO), Neurocrine Biosciences (NBIX), Sarepta Therapeutics (SRPT), Exelixis (EXEL), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Inovio Pharmaceuticals (INO). Who are La Jolla Pharmaceutical's key executives? La Jolla Pharmaceutical's management team includes the folowing people: Dr. George F. Tidmarsh, Pres, CEO, Sec. & Director (Age 59)Mr. Dennis M. Mulroy, Chief Financial Officer (Age 64)Ms. Jennifer A. Carver, Chief Operating Officer (Age 65)Mr. James M. Rolke, Chief Scientific Officer (Age 50)Dr. Lakhmir S. Chawla, Chief Medical Officer (Age 48) Who are La Jolla Pharmaceutical's major shareholders? La Jolla Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Trellus Management Company LLC (0.10%) and Virtu Financial LLC (0.04%). Company insiders that own La Jolla Pharmaceutical stock include George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Laura L Douglass, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Institutional Ownership Trends for La Jolla Pharmaceutical. Which institutional investors are buying La Jolla Pharmaceutical stock? LJPC stock was purchased by a variety of institutional investors in the last quarter, including Trellus Management Company LLC and Virtu Financial LLC. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for La Jolla Pharmaceutical. How do I buy shares of La Jolla Pharmaceutical? Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is La Jolla Pharmaceutical's stock price today? One share of LJPC stock can currently be purchased for approximately $7.61. How big of a company is La Jolla Pharmaceutical? La Jolla Pharmaceutical has a market capitalization of $206.05 million and generates $10.06 million in revenue each year. The biopharmaceutical company earns $-199,470,000.00 in net income (profit) each year or ($7.85) on an earnings per share basis. La Jolla Pharmaceutical employs 169 workers across the globe. What is La Jolla Pharmaceutical's official website? The official website for La Jolla Pharmaceutical is http://www.lajollapharmaceutical.com. How can I contact La Jolla Pharmaceutical? La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected] MarketBeat Community Rating for La Jolla Pharmaceutical (NASDAQ LJPC)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 287 (Vote Outperform)Underperform Votes: 245 (Vote Underperform)Total Votes: 532MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical and other stocks. Vote "Outperform" if you believe LJPC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LJPC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/24/2019 by MarketBeat.com StaffFeatured Article: What is the Consumer Price Index (CPI)?